Hyperkeratosis of nipple skin during sorafenib treatment.
Frigerio
Marta
M
Santi
Valentina
V
Di Micoli
Antonio
A
Trevisani
Franco
F
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000009:adverse effects*; D001941:Breast Diseases / Q000139:chemically induced; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy; D006801:Humans; D007642:Keratosis / Q000139:chemically induced*; D008113:Liver Neoplasms / Q000188:drug therapy; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D009558:Nipples / Q000187:drug effects / Q000473:pathology*; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D000077157:Sorafenib
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib